What Is Anaplastic Oligodendroglioma?
Anaplastic oligodendroglioma is a WHO grade 3 brain tumor. It grows from oligodendrocytes, specialized cells that wrap nerve fibers in a protective coating called myelin. The word "anaplastic" means the tumor cells look very abnormal under a microscope and divide faster than lower-grade tumors.
Today, the diagnosis requires two molecular features: a mutation in the IDH1 or IDH2 gene, and a combined deletion of chromosome arms 1p and 19q, called 1p/19q codeletion. Both must be present for a tumor to be classified as an oligodendroglioma. According to the National Cancer Institute, the 2021 WHO brain tumor classification now defines oligodendroglioma by these molecular markers.
This molecular identity matters for both prognosis and treatment. It sets anaplastic oligodendroglioma apart from other high-grade gliomas and explains why these tumors often respond well to chemotherapy, at least initially. It also creates specific weaknesses that newer targeted therapies can exploit.
Standard First-Line Treatment
For most patients, treatment begins with surgery to remove as much tumor as safely possible. After surgery, the standard approach pairs radiation therapy with chemotherapy.
The main chemotherapy regimen studied is PCV, a combination of procarbazine, lomustine (CCNU), and vincristine. Two landmark randomized trials, EORTC 26951 and RTOG 9402, showed that patients with 1p/19q-codeleted tumors who received radiation plus PCV chemotherapy lived significantly longer than those who received radiation alone. The joint final report from these trials found median overall survival exceeding 14 years in codeleted patients who received combined therapy, which is an excellent result for a grade 3 brain tumor.
Temozolomide (TMZ), an oral chemotherapy drug, is used at many centers as an alternative to PCV, partly because it has fewer side effects. Both regimens work, but doctors have more long-term data for PCV in grade 3, 1p/19q-codeleted disease. The Mayo Clinic treatment overview notes that the choice between PCV and TMZ depends on your situation and your hospital's experience.
Despite these strong initial responses, recurrence is expected in virtually all patients with anaplastic oligodendroglioma.
Why Does Anaplastic Oligodendroglioma Come Back?
To understand recurrence, look at how tumor cells survive treatment in the first place.
- Infiltrative growth limits surgical cure. Oligodendrogliomas spread individual cells along normal brain pathways. Even if the surgery looks complete on MRI, microscopic tumor cells remain in surrounding tissue. Radiation targets the tumor bed and a margin around it, but it isn't safe to give that much radiation to the whole brain.
- Clonal evolution under treatment pressure. Chemotherapy and radiation kill the most vulnerable tumor cells. A small population with different genetic features may survive and eventually regrow. This process, called clonal evolution, means the recurrent tumor may behave differently from the original. Some recurrent oligodendrogliomas show changes in 1p/19q status and new TP53 mutations not present at initial diagnosis, suggesting the tumor can change over time.
- IDH mutation and the 2-HG oncometabolite. The IDH mutation that defines these tumors produces an abnormal metabolite called 2-hydroxyglutarate (2-HG). 2-HG disrupts normal gene regulation and keeps tumor cells in an immature, growing state. Even when treatment shrinks the tumor, surviving IDH-mutant cells continue to generate 2-HG, sustaining a tumor-promoting environment. This is why IDH inhibition has become a major focus of research.
- TERT promoter mutations and telomere maintenance. Most oligodendrogliomas carry TERT promoter mutations that allow tumor cells to maintain the ends of their chromosomes during repeated divisions. This makes cells resistant to the cellular aging that would otherwise limit their growth.
- CIC and FUBP1 alterations. Mutations in CIC and FUBP1, genes commonly affected alongside 1p/19q codeletion, change how genes work and may make tumors harder to treat over time.
In summary: recurrence happens because surgery and radiation cannot eliminate every tumor cell, and chemotherapy lets resistant cells survive. The tumor's genes help those surviving cells keep growing.
Recognizing Recurrence
Follow-up MRI scans usually show recurrence. Imaging may show a new area of contrast enhancement, expansion of FLAIR signal abnormality, or signs that the tumor is becoming more aggressive.
Distinguishing true recurrence from treatment-related tissue changes is hard. Radiation can cause local damage that looks like tumor on an MRI, a problem called pseudoprogression or radiation necrosis. Advanced imaging techniques such as perfusion MRI, MR spectroscopy, or PET scanning can help tell the difference. In some cases, repeat biopsy or re-surgery might be needed to confirm recurrence and check the tumor's updated molecular profile.
Re-Surgery at Recurrence
If the recurrent tumor is in an accessible location, a second resection may shrink the tumor, relieve neurological symptoms, and provide fresh tissue to test. Re-surgery does not cure the disease, but it can slow progression and improve function in some patients. Repeat pathology is especially valuable when tumor behavior has changed since the original diagnosis, since the tumor may have changed in ways that open new options.
Second-Line Chemotherapy
The choice of salvage chemotherapy depends partly on what was used first:
- Patients who received radiation plus PCV first-line are often offered temozolomide at recurrence. A phase II study from the EORTC Brain Tumor Group found that TMZ helped some patients with recurrent oligodendroglioma who had already received PCV, with the best results in tumors with 1p/19q codeletion and MGMT promoter methylation.
- Patients who received TMZ first may be offered lomustine (CCNU) or a lomustine-based regimen at recurrence.
- Re-challenge with the original regimen is sometimes considered after not needing treatment for a while, particularly with TMZ.
A retrospective analysis found that temozolomide salvage chemotherapy for recurrent anaplastic oligodendroglioma helped many patients, with responses tied to 1p/19q codeletion and MGMT methylation status. These molecular features matter at recurrence, just as they do at initial diagnosis.
Anti-Angiogenic Therapy
Bevacizumab is an antibody that blocks VEGF, a protein tumors use to grow new blood vessels. In recurrent high-grade oligodendroglial tumors, bevacizumab-based regimens show early promise in preliminary studies, though randomized trial data specific to oligodendroglioma are limited. Doctors sometimes use it for patients when standard drugs don't work or who have lots of swelling from the tumor. For a closer look at how bevacizumab works in recurrent high-grade glioma and what to expect during treatment, see our related article: Bevacizumab for Recurrent Glioblastoma: What It Actually Does, Who It Helps, and What to Expect.
IDH Inhibition: Vorasidenib
A new treatment option has emerged for IDH-mutant gliomas: oral IDH inhibitors that cross into the brain. In August 2024, the FDA approved vorasidenib (Voranigo) for adults and pediatric patients 12 and older with grade 2 IDH-mutant astrocytoma or oligodendroglioma following surgery. In the INDIGO trial, the drug cut the risk of tumor growth by 61% compared with placebo.
Vorasidenib crosses the blood-brain barrier and blocks the mutant IDH enzyme, cutting off production of 2-HG. Doctors are testing whether this approach may help patients with grade 3 oligodendrogliomas as well, particularly for non-enhancing residual or recurrent disease. Studies are looking at vorasidenib for grade 3 tumors, and this is an active area of study. Whether this translates to approved uses for grade 3 disease is still being determined.
Re-Irradiation
Some patients far enough out from their original radiation treatment may be able to get re-irradiation, often using highly focused techniques such as stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT). It depends on how much radiation the surrounding brain already received, where the tumor came back, and how long since the first radiation. Doctors usually check if this option is possible at a neuro-oncology center that specializes in radiation.
Clinical Trials
Clinical trials are often the best option for patients with recurrent anaplastic oligodendroglioma, particularly those who've tried many other treatments. Researchers are testing stronger IDH inhibitors, immunotherapy approaches such as checkpoint inhibitors and adoptive cell therapy, PARP inhibitors, and new combinations. Searching ClinicalTrials.gov with the terms "oligodendroglioma" and "recurrent" is a good place to start. Academic brain tumor centers affiliated with ALLIANCE or NRG cooperative groups often open oligodendroglioma-specific trials that may not be available at community oncology practices.
Molecular Profiling at Recurrence
The tumor's molecular profile can change over time. A recurrent oligodendroglioma may get new mutations in TP53, CDKN2A/B, or other genes that change how the tumor acts and how it responds to treatment. Re-biopsy at recurrence, when feasible and safe, gives newer information and may reveal targets for clinical trials or off-label strategies. See our related article for more on how molecular markers shape treatment decisions across IDH-mutant gliomas: IDH-Mutant Glioma vs. Glioblastoma: Why Your Diagnosis Type Changes Everything About Treatment and Prognosis.
Integrative and Supportive Approaches
Some patients ask about diet-based and complementary methods alongside salvage therapy. Research into areas such as the ketogenic diet, caloric restriction, and certain natural compounds is ongoing in IDH-mutant gliomas and related tumor types. None of these have been proven to work as well as standard treatment for this specific tumor type. What they may offer—support for handling treatment side effects, managing fatigue, and nutritional support—is best discussed with your care team and a certified integrative oncology provider. Our overview of The Ketogenic Diet and Glioblastoma: What the Evidence Actually Says provides context on metabolic therapy concepts, with the understanding that what works for glioblastoma may not work for oligodendroglioma.
Quality of Life and Long-Term Monitoring
Many patients with anaplastic oligodendroglioma live for years, sometimes more than a decade, even after recurrence. That long timeline makes quality of life central to every treatment decision. Side effects from repeated treatment, fatigue, seizure management, and staying independent all matter just as much as controlling the tumor.
The American Brain Tumor Association provides patient-focused resources on monitoring, symptom management, and planning your care for oligodendroglioma. Follow-up MRI, typically every two to four months during active treatment and every three to six months during observation, is the standard way to watch for recurrence.
When to Talk to Your Doctor
Contact your care team promptly if you notice new or changing neurological symptoms: headaches different from your usual pattern, new weakness or numbness, speech changes, vision problems, or increased seizure activity. These might mean the tumor is growing or that treatment caused changes that need to be checked with a scan. If it's been more than three months since your last stable MRI, confirm that a follow-up scan is scheduled. At any recurrence discussion, ask if they can test the tumor again to see if it's changed and whether any open clinical trials match your updated tumor profile.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.